Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b randomized double-blind placebo-controlled study of 2-dose and 3-dose V160 CMV vaccine regimens in CMV-seronegative healthy women
MOH_2018-04-29_002116Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2018
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of V160 in cytomegalovirus disease (CMV) (3 arms), sponsored by Merck & Co. Primary endpoints: Efficacy of three-dose V160 regimen and Safety and tolerability of two-dose and three-dose V160 regimens. Started Mar 2018; status: completed.
02
Drugs
V160
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on MOH_2018-04-29_002116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-04-29_002116.